골다공증 환자에게서 MRONJ(Medication-related osteonecrosis of the jaw)를 유발할 수 있는 국소위험인자에 대한 고찰
The study of the risk factors related to MRONJ(Medication-related osteonecrosis of the jaw) in osteoporosis patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recently, many side effects such as bone necrosis have been reported during dental treatment for patients with osteoporosis as an underlying disease. In particular, osteoporosis is on the rise every year in menopause women and elderly patients, and occurs in connection with bisphosphonate medication. Such medication-related osteonecrosis of the jaw is often caused by surgical dental treatment, and it is difficult to cure when it occurs, so prevention is important. Surgical treatment may be required in the oral Preparation process for extraction or prosthetic repair due to periodontal disease, and for the successful treatment of osteoporosis patients, dentists should fully understand and pay attention to the treatment of osteoporosis patients.
Abstract
Recently, many side effects such as bone necrosis have been reported during dental treatment for patients with osteoporosis as an underlying disease. In particular, osteoporosis is on the rise every year in menopause women and elderly patients, and occurs in connection with bisphosphonate medication. Such medication-related osteonecrosis of the jaw is often caused by surgical dental treatment, and it is difficult to cure when it occurs, so prevention is important. Surgical treatment may be required in the oral Preparation process for extraction or prosthetic repair due to periodontal disease, and for the successful treatment of osteoporosis patients, dentists should fully understand and pay attention to the treatment of osteoporosis patients.
참고문헌 (24)
- Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Taylor KH, "Osteonecrosis of the jaws induced by anti-RANK ligand therapy", Br J Oral Maxillofac Surg, 48, pp.221~223 (2010)
- 김경민, "Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 22(4), pp.151~165 (2015), 대한골대사학회
- Ruggiero SL, "American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014), American Association of Oral and Maxillofacial Surgeons
- Hadjidakis DJ, "Bone remodeling", Ann N Y Acad Sci, 1092, pp.385~396 (2006)
- Kim I, "The effect of systemically administered bisphosphonates on bony healing after tooth extraction and osseointegration of dental implants in the rabbit maxilla", Int J Oral Maxillofac Implants, 28, pp.1194~1200 (2013)
- Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw : integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Ann Oncol, 23, pp.1341~1347 (2012)
- Khan AA, "International task force on osteonecrosis of the jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus", J Bone Miner Res, 30, pp.3~23 (2015)
- Kumar SK, "The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy", Curr Osteoporos Rep, 8, pp.40~48 (2010)
- Lo JC, "Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68, pp.243~253 (2010)
- Henry D, "Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer : an analysis of data from patients with solid tumors", Support Care Cancer, 22(3), pp.679~687 (2014)
- Ng TL, "Long-term impact of bone-modifying agents for the treatment of bone metastases : a systematic review", Support Care Cancer, 29(2), pp.925~943 (2021)
- Lo JC, "Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68(2), pp.243~253 (2010)
- Administration USFaD, "Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Managment Advisory Committee", FDA, HHS, ~ (2011)
- Shudo A, "Long-term oral bisphosphonates delay healing after tooth extraction : a single institutional prospective study", Osteoporos Int, 29(10), pp.2315~2321 (2018)
- Gaudin E, "Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction : a systematic review and meta-analysis", J Clin Periodontol, 42(10), pp.922~932 (2015)
- Watts NB, "Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10Years", J Clin Endocrinol Metab, 104(6), pp.2443~2452 (2019)
- Mozzati M, "Tooth extraction in patients on zoledronic acid therapy", Oral Oncol, 48(9), pp.817~821 (2012)
- Scoletta M, "Tooth extractions in intravenous bisphosphonate-treated patients : a refined protocol", J Oral Maxillofac Surg, 71(6), pp.994~949 (2013)
- McGowan K, "Risk factors for medication-related osteonecrosis of the jaws : A systematic review", Oral Dis, 24(4), pp.527~536 (2018)
- Kyrgidis A, "Bisphosphonate-related osteonecrosis of the jaws : a case-control study of risk factors in breast cancer patients", J Clin Oncol, 26(28), pp.4634~4638 (2008)
- Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27(32), pp.5356~5362 (2009)
- Kim JW, "Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates", Bone, 57(1), pp.201~205 (2013)
- Ponnapakkam T, "Treating osteoporosis by targeting parathyroid hormone to bone", Drug Discov Today, 19(3), pp.204~208 (2014)